Equities Analysts Offer Predictions for VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn ($1.55) per share for the year, down from their prior forecast of ($1.26). The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The company had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%.

VNDA has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Down 1.2%

Shares of Vanda Pharmaceuticals stock opened at $3.98 on Monday. The company has a market capitalization of $234.56 million, a PE ratio of -12.44 and a beta of 0.69. Vanda Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $6.75. The stock’s fifty day simple moving average is $4.50 and its 200 day simple moving average is $4.65.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Quantinno Capital Management LP acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $48,000. Linden Thomas Advisory Services LLC acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $49,000. Nations Financial Group Inc. IA ADV acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $67,000. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $69,000. Finally, Virtu Financial LLC acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $72,000. Institutional investors own 88.14% of the company’s stock.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the company’s stock in a transaction on Friday, February 28th. The shares were purchased at an average price of $4.76 per share, with a total value of $47,600.00. Following the purchase, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at $11,241,834.80. This trade represents a 0.43% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have bought 32,000 shares of company stock valued at $151,180 in the last 90 days. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.